BRCA1 and breast carcinoma: Ongoing studies assessing the safety of additional risk-reducing options, such as salpingectomy with delayed oophorectomy (NCT01907789) and the BRCA-P trial studying the effect of denosumab on breast cancer risk in BRCA1 P/LPV carriers (NCT04711109), may offer more options with a potentially lower rate of deleterious effects on quality of life in the future.